Dublin medtech OncoMark raises €2.1m in funding
Firm ends to prevent ineffective treatment for early stage breast cancer
Company: Oncomark
Done deal:€2.1m investment
The clincher:“OncoMark aims to prevent early stage breast cancer patients’ exposure to ineffective treatment and needless toxicity” - Orla Rimmington, partner, Kernel Capital
OncoMark, the Dublin medtech developing early-stage diagnostic technology for breast cancer patients, has raised funding of €2.1 million.
Investors include Bank of Ireland Kernel Capital Venture Funds, the Irrus Investments syndicate and Galway HBAN MedTech syndicate. The round follows €2.7 million in investment secured by ...